Literature DB >> 22278231

Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.

Kathleen McCaffrey1, Irene Boo, Kevin Tewierek, Mark L Edmunds, Pantelis Poumbourios, Heidi E Drummer.   

Abstract

Hepatitis C virus glycoprotein E2 contains 18 conserved cysteines predicted to form nine disulfide pairs. In this study, a comprehensive cysteine-alanine mutagenesis scan of all 18 cysteine residues was performed in E1E2-pseudotyped retroviruses (HCVpp) and recombinant E2 receptor-binding domain (E2 residues 384 to 661 [E2(661)]). All 18 cysteine residues were absolutely required for HCVpp entry competence. The phenotypes of individual cysteines and pairwise mutation of disulfides were largely the same for retrovirion-incorporated E2 and E2(661), suggesting their disulfide arrangements are similar. However, the contributions of each cysteine residue and the nine disulfides to E2 structure and function varied. Individual Cys-to-Ala mutations revealed discordant effects, where removal of one Cys within a pair had minimal effect on H53 recognition and CD81 binding (C486 and C569) while mutation of its partner abolished these functions (C494 and C564). Removal of disulfides at C581-C585 and C452-C459 significantly reduced the amount of E1 coprecipitated with E2, while all other disulfides were absolutely required for E1E2 heterodimerization. Remarkably, E2(661) tolerates the presence of four free cysteines, as simultaneous mutation of C452A, C486A, C569A, C581A, C585A, C597A, and C652A (M+C597A) retained wild-type CD81 binding. Thus, only one disulfide from each of the three predicted domains, C429-C552 (DI), C503-C508 (DII), and C607-C644 (DIII), is essential for the assembly of the E2(661) CD81-binding site. Furthermore, the yield of total monomeric E2 increased to 70% in M+C597A. These studies reveal the contribution of each cysteine residue and the nine disulfide pairs to E2 structure and function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278231      PMCID: PMC3302498          DOI: 10.1128/JVI.05396-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.

Authors:  Heidi E Drummer; Kirilee A Wilson; Pantelis Poumbourios
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs.

Authors:  K Kitadokoro; D Bordo; G Galli; R Petracca; F Falugi; S Abrignani; G Grandi; M Bolognesi
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

3.  Characterization of the envelope glycoproteins associated with infectious hepatitis C virus.

Authors:  Gabrielle Vieyres; Xavier Thomas; Véronique Descamps; Gilles Duverlie; Arvind H Patel; Jean Dubuisson
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

4.  The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection.

Authors:  Ignacio Benedicto; Francisca Molina-Jiménez; Birke Bartosch; François-Loïc Cosset; Dimitri Lavillette; Jesús Prieto; Ricardo Moreno-Otero; Agustín Valenzuela-Fernández; Rafael Aldabe; Manuel López-Cabrera; Pedro L Majano
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

5.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

6.  Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.

Authors:  Jillian Whidby; Guaniri Mateu; Hannah Scarborough; Borries Demeler; Arash Grakoui; Joseph Marcotrigiano
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

7.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

8.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.

Authors:  Johanna Fraser; Irene Boo; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Biol Chem       Date:  2011-07-15       Impact factor: 5.157

10.  Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.

Authors:  Birke Bartosch; Jean Dubuisson; François-Loïc Cosset
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

View more
  17 in total

1.  Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.

Authors:  Jennifer M Pfaff-Kilgore; Edgar Davidson; Kathryn Kadash-Edmondson; Mayda Hernandez; Erin Rosenberg; Ross Chambers; Matteo Castelli; Nicola Clementi; Nicasio Mancini; Justin R Bailey; James E Crowe; Mansun Law; Benjamin J Doranz
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

2.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 3.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

4.  Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein.

Authors:  Ahmed Wahid; François Helle; Véronique Descamps; Gilles Duverlie; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 5.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

Review 6.  Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design.

Authors:  Alexander W Tarr; Tanvi Khera; Kathrin Hueging; Julie Sheldon; Eike Steinmann; Thomas Pietschmann; Richard J P Brown
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

Review 7.  Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion.

Authors:  Gabrielle Vieyres; Jean Dubuisson; Thomas Pietschmann
Journal:  Viruses       Date:  2014-03-11       Impact factor: 5.048

8.  Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.

Authors:  Radhika Gopal; Kelli Jackson; Netanel Tzarum; Leopold Kong; Andrew Ettenger; Johnathan Guest; Jennifer M Pfaff; Trevor Barnes; Andrew Honda; Erick Giang; Edgar Davidson; Ian A Wilson; Benjamin J Doranz; Mansun Law
Journal:  PLoS Pathog       Date:  2017-12-18       Impact factor: 6.823

Review 9.  Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development.

Authors:  Eric A Toth; Andrezza Chagas; Brian G Pierce; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

Review 10.  Early events in foamy virus-host interaction and intracellular trafficking.

Authors:  Ursula Berka; Martin Volker Hamann; Dirk Lindemann
Journal:  Viruses       Date:  2013-04-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.